Interestingly, a large genome-wide association study (GWAS) on EAC performed by the German Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON) including about 1065 EAC cases and 1019 controls identified variants of GATA6 to be strongly associated with the disease reflecting its central role within the tumor development (Becker et al. 2015). This evidence concerns the gene GATA6 and esophageal adenocarcinoma.